| 1 |
NCT01733927 |
Completed |
An Evaluation of a Rapid Test for HIV |
|
- Device: Rapid testing for HIV
|
Interventional |
Phase 3 |
- Pontificia Universidad Catolica de Chile
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- The sensitivity and specificity of a rapid test in oral fluid (OraQuick Advance)compare to the ELISA test for HIV.
- The number of people who received their result from the ELISA for HIV test, versus the number of people who receives their OQA results.
|
497 |
All |
18 Years and older (Adult, Senior) |
NCT01733927 |
DIEECII #3 |
|
May 2010 |
November 2010 |
March 2011 |
November 27, 2012 |
November 27, 2012 |
|
- School of Nursing, Pontificia Universidad Catolica de Chile
Macul, Santiago, Chile
|
| 2 |
NCT01751620 |
Completed |
Project ACCEPT: Engaging Newly Diagnosed HIV+ Youth in Care |
- HIV Positive Youth That Are Newly Engaged in Care
|
- Behavioral: Project ACCEPT
- Behavioral: HEALTH
|
Interventional |
Not Applicable |
- University of North Carolina, Chapel Hill
- National Institute on Drug Abuse (NIDA)
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Examine the efficacy of Project ACCEPT compared with an attention-controlled health education comparison intervention
- Explore the relationship between HIV biomarkers and participant's level of engagement in care
|
167 |
All |
16 Years to 24 Years (Child, Adult) |
NCT01751620 |
ATN 108 |
|
January 2013 |
June 2015 |
June 2015 |
December 18, 2012 |
February 28, 2017 |
|
- University of Miami School of Medicine
Miami, Florida, United States - Stroger Hospital and the CORE Center
Chicago, Illinois, United States - Wayne State University
Detroit, Michigan, United States - St. Jude Childrens Research Hospital
Memphis, Tennessee, United States
|
| 3 |
NCT01751100 |
Withdrawn |
The Feasibility of Using a General Health Screen to Increase HIV Testing in Community Pharmacies |
|
- Behavioral: HIV Test Offer
- Behavioral: General Health Screen Offer
|
Interventional |
Not Applicable |
- North Bronx Healthcare Network
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Care Provider)
- Primary Purpose: Prevention
|
- Acceptance of HIV Testing
- Proportion of African immigrants that accept HIV testing
- Proportion of IDU that accept HIV testing
- (and 2 more...)
|
0 |
All |
18 Years to 64 Years (Adult) |
NCT01751100 |
RFA-MH-13-092-001 |
|
July 2013 |
May 2016 |
July 2016 |
December 17, 2012 |
May 8, 2015 |
|
- Albert Einstein College of Medicine
Bronx, New York, United States
|
| 4 |
NCT01731691 |
Terminated |
Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease |
|
- Biological: α1 Proteinase Inhibitor
|
Interventional |
Phase 2
Phase 3 |
- Institute for Human Genetics and Biochemistry
- AIDS Community Research Initiative of America
- Grifols Biologicals Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- CD4 counts
- cholesterol levels
|
12 |
All |
18 Years to 65 Years (Adult) |
NCT01731691 |
Prolastin-C in HIV disease |
|
April 2012 |
July 2014 |
July 2014 |
November 22, 2012 |
December 23, 2014 |
|
- ACRIA
New York, New York, United States
|
| 5 |
NCT01751646 |
Completed |
Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART |
|
- Dietary Supplement: Vitamin D3 50,000 IU
- Dietary Supplement: Vitamin D3 placebo
|
Interventional |
Not Applicable |
- Westat
- National Institute on Drug Abuse (NIDA)
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Diagnostic
|
- Compare the percent change from baseline to week 48 in DXA-measured BMD at the spine for the randomized study groups
- Compare change from baseline to week 24 of BMC of whole body and BMD of spine, total hip, and femoral neck for the randomized study groups
- Compare change from baseline to week 48 of BMC of whole body and BMD of spine, total hip, and femoral neck for the randomized study groups
- (and 35 more...)
|
214 |
All |
16 Years to 24 Years (Child, Adult) |
NCT01751646 |
ATN 109 Version 2.0 |
|
October 2012 |
June 2016 |
June 2016 |
December 18, 2012 |
July 4, 2016 |
|
- Children's Hopsital of Los Angeles
Los Angeles, California, United States - University of Southern California - NICHD Westat Site
Los Angeles, California, United States - Childrens National Medical Center
Washington, District of Columbia, United States - (and 16 more...)
|
| 6 |
NCT01876966 |
Completed |
Interaction Between Etravirine or Darunavir/Ritonavir and Artemether / Lumefantrine |
|
- Drug: Etravirine
- Drug: Darunavir/ritonavir
- Drug: artemether/lumefantrine
|
Interventional |
Phase 1 |
- Janssen Pharmaceutica N.V., Belgium
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- effect of ETR or DRV/rtv on the plasma concentrations of artemether, lumefantrine and dihydroartemisinin
- effect of ETR or DRV/rtv on the Area under the concentration-time curve (AUC) in plasma for artemether, lumefantrine and dihydroartemisinin
- Plasma concentrations of ETR, DRV and rtv
- (and 4 more...)
|
33 |
All |
18 Years to 55 Years (Adult) |
NCT01876966 |
CR018409
2010-023289-31
TMC125VIR1001 |
DDI Coartem |
March 2011 |
July 2011 |
July 2011 |
June 13, 2013 |
June 13, 2013 |
|
|
| 7 |
NCT01734850 |
Completed |
Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection |
- Human Immunodeficiency Virus
|
- Drug: Busulfan
- Biological: Cal-1 modified HSPC
- Biological: Cal-1 modified CD4+ T lymphocytes
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Feasibility and safety of the introduction of Cal-1 into HSPC and CD4+ T lymphocyte cell populations, and the associated delivery procedures.
- The benefit of busulfan conditioning in impacting efficacy of Cal-1 in controlling HIV-1 infection
|
12 |
All |
18 Years to 65 Years (Adult) |
NCT01734850 |
CAL-USA-11 |
|
April 2013 |
September 2017 |
November 2017 |
November 28, 2012 |
February 7, 2018 |
|
- UCLA CARE Center
Los Angeles, California, United States - Quest Clinical Research
San Francisco, California, United States
|
| 8 |
NCT01751568 |
Recruiting |
Evaluating the Safety, Tolerance, and Pharmacokinetics of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in Infants and Children Infected With HIV and TB |
- HIV Infections
- Tuberculosis
|
|
Interventional |
Phase 1
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Termination from treatment due to adverse events of greater than or equal to Grade 3 deemed at least possibly related to raltegravir
- Death, Grade 4 life-threatening adverse events deemed at least possibly related to raltegravir
- Grade 4 non-life threatening adverse events deemed as probably or definitely related to raltegravir
- (and 4 more...)
|
108 |
All |
up to 11 Years (Child) |
NCT01751568 |
P1101
11831
IMPAACT P1101 |
|
May 2014 |
May 2019 |
|
December 18, 2012 |
May 9, 2017 |
|
- Soweto IMPAACT CRS
Johannesburg, Gauteng, South Africa - Wits RHI Shandukani Research Centre CRS
Johannesburg, Gauteng, South Africa - Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS
Cape Town, Western Cape Province, South Africa - Fam-Cru Crs
Tygerberg, Western Cape Province, South Africa
|
| 9 |
NCT01746199 |
Unknown † |
Efficacy of Antifolates Against Malaria in HIV-infected Pregnant Women and the Emergence of Induced Resistance in Plasmodium Falciparum |
- Malaria in Pregnancy
- HIV Infection
|
- Drug: cotrimoxazole daily prophylaxis
- Drug: sulphadoxine-pyrimethamine
|
Interventional |
Phase 3 |
- Institut Pasteur
- Institut Pasteur de Bangui
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- placental parasitaemia
- observance CTM prophylaxis
- occurrence of specific events related to the effectiveness of CTM prophylaxis and IPT-SP
- occurence of adverse events
|
300 |
Female |
18 Years and older (Adult, Senior) |
NCT01746199 |
2012-03 |
MACOMBA |
December 2013 |
October 2015 |
|
December 10, 2012 |
November 15, 2013 |
|
- Maternité de l'Hôpital communautaire
Bangui, Central African Republic - Maternité de l'Hôpital de l'Amitié
Bangui, Central African Republic - Maternité de la Gendarmerie Nationale
Bangui, Central African Republic - Maternité du centre de santé des Castors
Bangui, Central African Republic
|
| 10 |
NCT01733693 |
Completed |
Neurocognitive Effects of Opiate Agonist Treatment |
- Opioid-Related Disorders
- HIV
- HIV Infections
|
- Drug: Buprenorphine
- Drug: Methadone
|
Interventional |
Phase 4 |
- Albert Einstein College of Medicine, Inc.
- National Institute on Drug Abuse (NIDA)
- Montefiore Medical Center
- Fordham University
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Global Neurocognitive Function
- Domain-Specific Neurocognitive Function (i.e. in the domains of executive functioning, learning, memory, attention/working memory, processing speed, motor, and verbal functioning).
|
135 |
All |
18 Years to 68 Years (Adult, Senior) |
NCT01733693 |
2012-433
1R01DA032552-01A1 |
NEO |
January 2013 |
June 2017 |
June 2017 |
November 27, 2012 |
July 6, 2017 |
|
- Fordham University
The Bronx, New York, United States - Albert Einstein College of Medicine of Yeshiva University
The Bronx, New York, United States
|
| 11 |
NCT01748968 |
Completed |
Veterans Living With HIV/AIDS: A Pilot Study Examining Risk Factors Associated With Self-Directed Violence |
- Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS)
- Self-Directed Violence
|
|
Observational |
|
- VA Eastern Colorado Health Care System
- Public Health Grant Program, Veterans Health Administration Office of Public Health
|
U.S. Fed / Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Semi-Structured Interview
|
20 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT01748968 |
12-0755 |
|
September 2012 |
September 2015 |
September 2015 |
December 13, 2012 |
December 14, 2015 |
|
- Denver VA
Denver, Colorado, United States
|
| 12 |
NCT01749007 |
Completed |
Assessment of Cognitive Functioning as it Relates to Risk for Suicide in Veterans With HIV/AIDS |
|
|
Observational |
|
- VA Eastern Colorado Health Care System
|
U.S. Fed |
- Observational Model: Cohort
- Time Perspective: Other
|
- Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV)
- Trail Making Test (TMT): Parts A & B
- California Verbal Learning Test, Second Edition (CVLT-II)
- (and 16 more...)
|
50 |
All |
18 Years to 65 Years (Adult) |
NCT01749007 |
12-1039 |
|
November 2012 |
August 2016 |
January 2017 |
December 13, 2012 |
May 15, 2017 |
|
- Eastern Colorado Health Care System
Denver, Colorado, United States
|
| 13 |
NCT01736761 |
Completed |
A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiretroviral Combination of Rilpivirine and Ritonavirboosted Darunavir in Therapy-naive HIV-1 Infected Patients. |
|
- Drug: Darunavir, Ritonavir and Rilpivirine
|
Interventional |
Phase 4 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Virologic suppression after 48 weeks of therapy with the study regime
- To explore the virologic response to this combination rilpivirine and ritonavir-boosted darunavir at weeks 4, 8, 12 and 24 of therapy.
|
36 |
All |
18 Years to 65 Years (Adult) |
NCT01736761 |
SSAT 049 |
|
December 2012 |
March 2015 |
March 2015 |
November 29, 2012 |
June 16, 2017 |
|
- St Stephen's AIDS Trust
London, United Kingdom
|
| 14 |
NCT01731574 |
Completed |
DDI Potential: Dapivirine Vaginal Ring and Miconazole Nitrate |
|
- Drug: dapivirine
- Drug: miconazole
|
Interventional |
Phase 1 |
- International Partnership for Microbicides, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Dapivirine Area under the concentration time curve (AUC)
|
36 |
Female |
18 Years to 40 Years (Adult) |
NCT01731574 |
IPM 028 |
|
December 2012 |
October 2013 |
October 2013 |
November 22, 2012 |
September 8, 2017 |
|
- SGS Life Sciences
Lange Beeldekensstraat 267, Antwerpen, Belgium
|
| 15 |
NCT01741844 |
Completed |
A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Intelence |
- Acquired Immune Deficiency Syndrome
|
|
Observational |
|
- Janssen Korea, Ltd., Korea
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Number of patients with adverse events
- Number of patients with viral load
- Number of patients with CD4 T-cell count
|
57 |
All |
18 Years and older (Adult, Senior) |
NCT01741844 |
CR100806
TMC125HIV4017
Intelene PMS
ETR-C-11-KR-001-V04 |
|
September 2012 |
July 2014 |
July 2014 |
December 5, 2012 |
April 4, 2016 |
|
- Dae-Gu, Korea, Republic of
|
| 16 |
NCT01741831 |
Completed |
A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista |
- Acquired Immune Deficiency Syndrome
|
|
Observational |
|
- Janssen Korea, Ltd., Korea
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Number of patients with adverse events
- Number of patients with viral load
- Number of patients with CD4 T-cell count
|
225 |
All |
18 Years and older (Adult, Senior) |
NCT01741831 |
CR100805
TMC114HIV4074
Prezista PMS
DRV-C-11-KR-001-V06 |
|
July 2012 |
October 2016 |
October 2016 |
December 5, 2012 |
December 5, 2016 |
|
- Dae-Gu, Korea, Republic of
|
| 17 |
NCT01813357 |
Unknown † |
Does Rosuvastatin Delay Progression of Atherosclerosis in HIV |
- HIV
- Cardiovascular Disease
|
- Drug: Rosuvastatin
- Other: Placebo
|
Interventional |
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Progression of carotid intima media thickness
- Rates of adverse events
|
102 |
All |
18 Years and older (Adult, Senior) |
NCT01813357 |
AH-491/12
ACTRN12612001082897 |
|
March 2013 |
January 2015 |
January 2017 |
March 19, 2013 |
July 15, 2014 |
|
- Alfred Hospital
Melbourne, Victoria, Australia - Hospitaux Universitaires de Geneve
Geneve, Switzerland
|
| 18 |
NCT01738555 |
Withdrawn |
A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects |
- Human Immunodeficiency Virus Infection
|
- Drug: amdoxovir 300 mg bid
- Drug: amdoxovir 500 mg bid
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- HIV-1 viral load
- Incidence of adverse events
- Changes in Immunologic Function (CD4 cell counts)
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT01738555 |
RFSP-AMDX-2012 |
|
April 2013 |
August 2014 |
October 2014 |
November 30, 2012 |
March 29, 2013 |
|
|
| 19 |
NCT01755754 |
Completed |
A Trial to Assess the Functionality of Female Condom With a Silicone Elastomer Vaginal Ring |
- Human Immunodeficiency Virus
|
- Combination Product: Silicone Elastomer Vaginal Ring
- Device: Female Condom
|
Interventional |
Phase 1 |
- International Partnership for Microbicides, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Total clinical failure rate
|
160 |
All |
18 Years to 45 Years (Adult) |
NCT01755754 |
IPM 033 |
|
August 2013 |
March 2014 |
March 2014 |
December 24, 2012 |
September 28, 2017 |
|
- California Family Health Council
Los Angeles, California, United States
|
| 20 |
NCT01755741 |
Completed |
Functionality of Male Condoms With a Silicone Elastomer Vaginal RIng |
- Human Immunodeficiency Virus
|
- Combination Product: Placebo Vaginal Ring
- Device: Condom
|
Interventional |
Phase 1 |
- International Partnership for Microbicides, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Total clinical failure rate (N slipped or broken/N total) off the penis or broke during intercourse or withdrawal, divided by the number of condoms used during intercourse.
|
70 |
All |
18 Years to 55 Years (Adult) |
NCT01755741 |
IPM 029 |
|
February 2013 |
October 2013 |
October 2013 |
December 24, 2012 |
March 29, 2018 |
|
- California Family Health Council
Berkeley, California, United States - California Family Health Council
Los Angeles, California, United States
|
| 21 |
NCT01768962 |
Completed |
Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% Gel |
|
- Drug: Once Daily Application of TFV RG 1% Gel
- Drug: Once Daily Application of TFV RG 1% gel - Rectal
- Drug: Once Daily Application of TFV RG 1% Gel - Vaginal
|
Interventional |
Phase 1 |
- CONRAD
- Division of AIDS
- National Institute of Allergy and Infectious Diseases (NIAID)
- (and 3 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
|
- Drug concentrations
- Number of adverse events Grade 2 or higher
|
14 |
Female |
21 Years to 45 Years (Adult) |
NCT01768962 |
MTN-014
5UM1AI068633
11885 |
|
April 2014 |
December 2014 |
December 2014 |
January 16, 2013 |
December 15, 2015 |
|
- Center for Infectious Disease Epidemiologic Research, Mailman School of Public Health, Columbia University
New York, New York, United States
|
| 22 |
NCT01766076 |
Completed
Has Results |
Atorvastatin for HAART Suboptimal Responders |
- Acquired Immune Deficiency Syndrome Virus
|
- Other: atorvastatin, Lipitor®
- Drug: Placebo
|
Interventional |
Phase 3 |
- Makerere University
- Vaccine and Gene Therapy Institute, Florida
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Percentage Change in Immune Activation Levels After 12 Weeks of Atorvastatin 80mg Daily
|
30 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT01766076 |
HS1258 |
|
January 2013 |
February 2014 |
March 2014 |
January 11, 2013 |
May 21, 2015 |
May 21, 2015 |
|
| 23 |
NCT01737359 |
Terminated |
A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects. |
- Human Immunodeficiency Virus Infection
|
- Drug: amdoxovir 300 mg bid
- Drug: amdoxovir 500 mg bid
- Drug: tenofovir DF 300 mg qd
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- HIV-1 viral load
- Safety and Tolerability- Incidence of adverse events and laboratory abnormalities
- Changes in Immunologic Function (CD4 cell counts)
|
2 |
All |
18 Years and older (Adult, Senior) |
NCT01737359 |
RFSP-AMDX-2010 |
|
December 2012 |
February 2013 |
March 2013 |
November 29, 2012 |
November 5, 2014 |
|
- Research Site
Rosario, Santa Fe, Argentina - Research Site
Rosario, Santa Fe, Argentina - Research Site
Buenos Aires, Argentina - (and 3 more...)
|
| 24 |
NCT01741350 |
Completed
Has Results |
Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users |
|
- Behavioral: Community-friendly Health Recovery Program
- Behavioral: Time-and-Attention-Matched Control Condition
|
Interventional |
Not Applicable |
- University of Connecticut
- National Institute on Drug Abuse (NIDA)
- APT Foundation, Inc.
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Demonstrated Drug Risk Reduction Skills (0-100%)
- Safer Drug Use (0-4)
- Drug-related HIV-risk Reduction Knowledge (0-1)
- (and 10 more...)
|
304 |
All |
18 Years and older (Adult, Senior) |
NCT01741350 |
H06-215
1R01DA022122-01A1 |
|
September 2006 |
May 2011 |
June 2012 |
December 4, 2012 |
February 27, 2014 |
February 27, 2014 |
- APT Foundation
New Haven, Connecticut, United States
|
| 25 |
NCT01748136 |
Completed |
Screening for Lung Cancer in the HIV Patient |
- Lung Cancer in the HIV Patient
|
- Device: CT Scan with Spirometry
|
Interventional |
Not Applicable |
- Sidney Kimmel Comprehensive Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Stage distribution of HIV-seropositive patients
- To create a specimen bank of serum, sputum, and tissue
|
200 |
All |
26 Years to 100 Years (Adult, Senior) |
NCT01748136 |
J0491
NA_00036809 |
NA_00036809 |
January 2006 |
September 2011 |
September 2011 |
December 12, 2012 |
October 13, 2016 |
|
|
| 26 |
NCT01751555 |
Completed |
Efficacy and Safety of TDF+3TC+EFV in Adults With HIV/HBV Coinfection |
|
- Drug: Regimen:TDF+3TC+EFV
|
Interventional |
Phase 4 |
- National Center for AIDS/STD Control and Prevention, China CDC
- Gilead Sciences
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients with HIV RNA below LDL and HBV DNA below 2.3log10 copies/ml at week 48
- Incidence of targeted adverse events over 48 weeks
|
100 |
All |
18 Years to 60 Years (Adult) |
NCT01751555 |
co-us-104-0405 |
|
February 2011 |
June 2013 |
June 2013 |
December 18, 2012 |
June 28, 2013 |
|
- National Center for AIDS/STD Control and Prevention, China CDC
Beijing, Beijing, China
|
| 27 |
NCT01751594 |
Completed |
Testing a Secondary Prevention Intervention for HIV-Positive Black Young Men Who Have Sex With Men |
|
- Behavioral: MOVE Intervention
- Behavioral: H4L Comparison Intervention
|
Interventional |
Not Applicable |
- University of North Carolina, Chapel Hill
- National Institute on Drug Abuse (NIDA)
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Finalize and manualize a critical consciousness based intervention for HIV positive B-YMSM
|
92 |
Male |
16 Years to 24 Years (Child, Adult) |
NCT01751594 |
ATN 104 |
|
April 2012 |
June 2014 |
June 2014 |
December 18, 2012 |
August 1, 2017 |
|
- Children's Hospital of Los Angeles
Los Angeles, California, United States - Stroger Hospital and the CORE Center
Chicago, Illinois, United States - Montefiore Medical Center
The Bronx, New York, United States - (and 2 more...)
|
| 28 |
NCT01740115 |
Completed |
Boston Alcohol Research Collaboration on HIV/AIDS (ARCH) Cohort |
- HIV Infection
- Alcohol Use
- Bone Disease
- Substance-Related Disorders
|
|
Observational |
|
- Boston Medical Center
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Annual mean percent change in hip (femoral neck) bone mineral density (g/cm2)
- Annual mean percent change in spine (trabecular bone) bone mineral density (g/cm2)
- Proportion with bone mineral density decrease of >6%
- (and 4 more...)
|
250 |
All |
18 Years and older (Adult, Senior) |
NCT01740115 |
U01AA020784 |
|
November 2012 |
March 2016 |
August 2016 |
December 4, 2012 |
September 12, 2016 |
|
- Boston Medical Center
Boston, Massachusetts, United States
|
| 29 |
NCT01744093 |
Active, not recruiting |
Doxycycline for COPD in HIV-Infected Patients |
- HIV
- Chronic Obstructive Pulmonary Disease (COPD)
- Emphysema
|
- Drug: Doxycycline
- Drug: Placebo (sugar pill)
|
Interventional |
Not Applicable |
- Weill Medical College of Cornell University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Number of participants with adverse events as a measure of safety and tolerability
- Measure of physiologic and biologic effects based on levels of MMP activity in epithelial lining fluid before and after study drug administration.
|
61 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT01744093 |
1208012780 |
|
July 17, 2014 |
October 25, 2017 |
June 30, 2018 |
December 6, 2012 |
January 10, 2018 |
|
- GeneticMedicine
New York, New York, United States
|
| 30 |
NCT01741311 |
Recruiting |
Secondary HIV Prevention and Adherence Among HIV-infected Drug Users |
- Risk Behavior
- Medication Adherence
- HIV
|
- Behavioral: 3H+ (Holistic Health for HIV)
- Behavioral: HHRP+ (Holistic Health Recovery Program)
|
Interventional |
Not Applicable |
- University of Connecticut
- National Institute on Drug Abuse (NIDA)
- Yale University
- APT Foundation, Inc.
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The proportion of participants free from HIV-transmission risk
- Antiretroviral therapy (ART) adherence
|
256 |
All |
18 Years and older (Adult, Senior) |
NCT01741311 |
H12-050
R01DA032290 |
|
September 2012 |
June 2018 |
June 2018 |
December 4, 2012 |
September 13, 2017 |
|
- APT Foundation
New Haven, Connecticut, United States
|
| 31 |
NCT01746758 |
Unknown † |
Mobile Phone Text Messaging Referral |
- HIV
- Sexually Transmitted Infections
- Contraception
- Pregnancy
|
- Behavioral: SMS text messaging referral
|
Interventional |
Not Applicable |
- Liverpool School of Tropical Medicine
- National Institute for Medical Research, Tanzania
- Ministry of Health and Social Welfare, Tanzania
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Increase the number of patients receiving reproductive health services at dispensary and health centre level after referral from a drug store.
- Referred number of patients attending HIV, STI, pregnancy prevention (including numbers of condoms, VCT, and post-abortion care) and treatment
- Referred number of patients attending other contraceptives (the pill, intra-uterine devices, injection, female condom and sterilisation where available)
- (and 3 more...)
|
700 |
All |
15 Years to 19 Years (Child, Adult) |
NCT01746758 |
11.94RS |
SMS4Health |
August 2012 |
January 2014 |
January 2014 |
December 11, 2012 |
December 11, 2012 |
|
- National Institute for Medical Research Tanzania
Mwanza, Tanzania
|
| 32 |
NCT01735708 |
Completed |
Treating Chronic Pain and Depression in HIV+ Patients in Primary Care Settings |
- Pain Interference
- Depression
- Antiretroviral Adherence
|
- Behavioral: HIVPASS
- Other: Health Education
|
Interventional |
Not Applicable |
- Butler Hospital
- Brown University
- National Institute of Nursing Research (NINR)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- pain interference
- depression
- antiretroviral adherence
|
23 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01735708 |
NR13438
R21NR013438 |
HIVPASS |
November 2012 |
August 2014 |
August 2015 |
November 28, 2012 |
November 11, 2015 |
|
- Butler Hospital
Providence, Rhode Island, United States
|
| 33 |
NCT01730131 |
Recruiting |
Natural History Study of Progressive Multifocal Leukoencephalopathy (PML) |
- Progressive Multifocal Leukoencephalopathy
|
|
Observational |
|
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Characterization of the baseline features of patients with PMLwith regards to clinical features imaging studies,immunological markers, and viral studies.
|
200 |
All |
2 Years and older (Child, Adult, Senior) |
NCT01730131 |
130017
13-N-0017 |
|
November 17, 2012 |
December 31, 2020 |
December 31, 2021 |
November 21, 2012 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
Create an RSS feed from your search for:
Download the search results for: